Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014 Vycom announced today that ... specializes in chemical process equipment, has selected its Flametec ... Facility for Rare Isotope Beams (FRIB). This involved ... line made with Vycom’s Flametec PVC-C and Kytec PVDF ... essential parts of FRIB’s linear accelerator (known as LINAC). ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
(Date:8/26/2014)... , Aug. 26, 2014  Guardant Health, a ... of oncology diagnostic products, has been recognized today ... Technology Pioneer . As an innovator in ... 24 companies across a wide variety of industries ... Guardant360 ® , Guardant Health,s first ...
(Date:8/26/2014)... , Aug. 26, 2014 Albany Molecular ... that William S. Marth , President and Chief ... Stanley Global Healthcare Conference on Monday, September 8, 2014 ... audio webcast of the presentation can be accessed at ... The webcast will be archived for 90 ...
Breaking Biology Technology:Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2
... Pipeline-Grade Renewable Natural Gas ... Manure and Other Waste Products, TARRYTOWN, N.Y., June ... leader in the renewable bioenergy industry,will today mark the ... with a ground breaking ceremony. The Dublin, Texas,facility, owned ...
... for,Analytical Cytometry has bestowed its President,s Award for ... work on the discovery and,characterization of embryonic-like stem ... Institute of the University of Louisville and has,employed ... "I am highly honored to have been ...
... WA, June 11 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ... that the first,patient has been treated in a ... advanced metastatic cancer. PX-12 is a proprietary small ... molecular,pathways that contribute to the growth, survival and ...
Cached Biology Technology:Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 2Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 3Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 4Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5Stem Cell Researcher Wins Award for Excellence for Work With the ImageStream(R) System 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3
(Date:8/26/2014)... are bringing a touch of color to glucose ... glucose monitoring material that changes color as glucose ... precise that doctors and patients may be able ... - something not possible using current point measurements ... to current continuous glucose monitoring technologies," said study ...
(Date:8/26/2014)... at the University of Illinois at Urbana-Champaign have ... paving the way for power-on-a-chip applications. , ... scale that amplify light and produce ultra-narrowband spectral ... electrical and computer engineering (ECE) at Illinois. "These ... power on a chip containing both electronic and ...
(Date:8/26/2014)... , August 26, 2014 ... Veröffentlichung von Oxygen Forensic Passware Analyst bekannt, ... die preisgekrönten Erfassungs- und Analysetools von Oxygen ... kombiniert.     Das neue Tool ... in einem einzigen nahtlosen Ablauf. Das neu ...
Breaking Biology News(10 mins):A glucose meter of a different color provides continuous monitoring 2A glucose meter of a different color provides continuous monitoring 3Symphony of nanoplasmonic and optical resonators produces laser-like light emission 2Oxygen Forensic Passware Analyst erfasst geschützte Mobilgerätedaten 2
... report describing the occurrence of pesticides in streams and ... are typically present throughout the year in most streams ... are less common in ground water. The report ... to affect humans. However in many streams, particularly ...
... a heart attack does not improve certain cardiac functions ... risk of death, according to a study in the ... widely available dietary supplement and is publicized as having ... sexual dysfunction, according to background information in the article. ...
... L-arginine following a heart attack does not improve certain ... an increased risk of death, according to a study ... is a widely available dietary supplement and is publicized ... failure and sexual dysfunction, according to background information in ...
Cached Biology News:Pesticides in the nation's streams and ground water 2Pesticides in the nation's streams and ground water 3Pesticides in the nation's streams and ground water 4An elephant tail 2Little known DNA repair enzyme may be a tumor suppressor gene 2
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... software is used to predict ... DNA sequence up to 3,200 ... placement of primers and GC ... denaturing gradient gel electrophoresis (DGGE), ...
... The Mini-Sub cell GT cell and PowerPac ... gel electrophoresis of nucleic acids in agarose gels. ... tank, lid with cables and electrodes, a 7 ... ruler, two casting gates, and two 1.5 mm ...
... PowerPac basic power supply are used for submerged ... gels. The mini format cell includes a buffer ... bubble. The PowerPac basic power supply, 100-120 and ... mA, and 75 W. Power cord and instructions ...
Biology Products: